Marinus Pharmaceuticals (MRNS) Stock Rating Reaffirmed by Mizuho

Mizuho reaffirmed their buy rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research report report published on Tuesday morning. They currently have a $13.00 price objective on the biopharmaceutical company’s stock.

“We highlighted our expectations for the phase 2 data in a previous note (available here). Magnolia is a multiple dose escalation study with ~60 patients randomized 1:1 with multiple dose cohorts and therefore not designed to hit statistical significance, in contrast to the phase 2 trial of Sage Therapeutics (SAGE, not rated) which was designed with a specific dose of brexanolone. In our view, the most important information to look for in the results will be a signal of efficacy along with information on a specific dose to be taken into Magnolia study.”,” Mizuho’s analyst wrote.

Other equities analysts have also issued reports about the stock. Cantor Fitzgerald set a $19.00 price target on shares of Marinus Pharmaceuticals and gave the stock a buy rating in a research report on Tuesday. BidaskClub lowered shares of Marinus Pharmaceuticals from a strong-buy rating to a buy rating in a research report on Friday, June 22nd. LADENBURG THALM/SH SH assumed coverage on shares of Marinus Pharmaceuticals in a research report on Wednesday, June 6th. They set a buy rating and a $20.00 price target on the stock. Finally, ValuEngine upgraded shares of Marinus Pharmaceuticals from a hold rating to a buy rating in a research report on Saturday, June 2nd. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus price target of $19.67.

MRNS stock opened at $9.36 on Tuesday. Marinus Pharmaceuticals has a 52 week low of $3.31 and a 52 week high of $9.87.

Marinus Pharmaceuticals (NASDAQ:MRNS) last released its earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.09). equities analysts forecast that Marinus Pharmaceuticals will post -0.73 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of MRNS. Trexquant Investment LP acquired a new position in Marinus Pharmaceuticals during the second quarter worth about $102,000. GSA Capital Partners LLP acquired a new position in Marinus Pharmaceuticals during the second quarter worth about $141,000. Barclays PLC acquired a new position in Marinus Pharmaceuticals during the first quarter worth about $232,000. Rhumbline Advisers acquired a new position in Marinus Pharmaceuticals during the second quarter worth about $245,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in Marinus Pharmaceuticals during the second quarter worth about $363,000. Hedge funds and other institutional investors own 63.64% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three different dose forms: intravenous (IV), capsule, and liquid.

Recommended Story: Market Capitalization and Individual Investors

Analyst Recommendations for Marinus Pharmaceuticals (NASDAQ:MRNS)

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply